Rivoceranib

Generic Name: Rivoceranib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Clinical Trials

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1

Recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Azacitidine Injection
Drug: Tucidinostat
Drug: Camrelizumab
Drug: Linperlisib
Drug: SHR2554
Drug: Apatinib
Drug: Dasatinib

First Posted Date: 2022-09-29

Last Posted Date: 2022-11-09

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 116

Registration Number: NCT05559008

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: camrelizumab& apatinib

First Posted Date: 2022-09-22

Last Posted Date: 2022-09-22

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 26

Registration Number: NCT05550025

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangzhou, China

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Phase 2

Not yet recruiting

Conditions: Locally Advanced Gastric Cancer

Interventions: Drug: Camrelizumab
Drug: Oxaliplatin
Drug: S1
Drug: Apatinib Mesylate
Drug: Nab paclitaxel

First Posted Date: 2022-09-01

Last Posted Date: 2022-09-01

Lead Sponsor: Fujian Medical University

Target Recruit Count: 203

Registration Number: NCT05524974

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib
Drug: Nab-paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2022-07-07

Last Posted Date: 2023-05-22

Lead Sponsor: West China Hospital

Target Recruit Count: 35

Registration Number: NCT05447702

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Phase 2

Conditions: Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Apatinib Mesylate
Drug: Camrelizumab

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 68

Registration Number: NCT05342389

Locations: 🇨🇳
The Sixth Affiliated hosipital, Sun Yat-Sen University, Guangzhou, Guangdong, China

A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rivoceranib

First Posted Date: 2022-03-18

Last Posted Date: 2022-04-18

Lead Sponsor: Elevar Therapeutics

Target Recruit Count: 60

Registration Number: NCT05287360

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Phase 2

Recruiting

Conditions: Sarcoma,Soft Tissue
Extremity
Trunk
Intensity-modulated Radiotherapy
Major Wound Complications
Targetd Therapy

Interventions: Drug: Apatinib Mesylate

First Posted Date: 2022-02-10

Last Posted Date: 2022-02-10

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT05235100

Locations: 🇨🇳
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Phase 2

Conditions: Targeted Therapy
Immunotherapy
Gastrointestinal Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib Mesylate

First Posted Date: 2022-02-07

Last Posted Date: 2022-02-07

Lead Sponsor: Harbin Medical University

Target Recruit Count: 150

Registration Number: NCT05225844

Locations: 🇨🇳
Harbin Medical University, Harbin, Heilongjiang, China

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2

Completed

Conditions: Immunotherapy
Gastrict Cancer

Interventions: Drug: Tislelizumab
Drug: Apatinib Mesylate
Drug: oxaliplatin
Drug: Tegafur

First Posted Date: 2022-02-03

Last Posted Date: 2025-03-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05223088

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, China

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: FOLFOX-HAIC
Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2022-01-20

Last Posted Date: 2024-11-27

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 214

Registration Number: NCT05198609

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy